CYP2A6 genetic variation and dexmedetomidine disposition.

Kohli U, Pandharipande P, Muszkat M, Sofowora GG, Friedman EA, Scheinin M, Wood AJ, Ely EW, Tyndale RF, Choi L, Stein CM, Kurnik D
Eur J Clin Pharmacol. 2012 68 (6): 937-42

PMID: 22271297 · PMCID: PMC3352974 · DOI:10.1007/s00228-011-1208-z

PURPOSE - There is a large interindividual variability in dexmedetomidine dose requirements for sedation of patients in intensive care units (ICU). Cytochrome P450 2A6 (CYP2A6) mediates an important route of dexmedetomidine metabolism, and genetic variation in CYP2A6 affects the clearance of other substrate drugs. We examined whether CYP2A6 genotypes affect dexmedetomidine disposition.

METHODS - In 43 critically ill ICU patients receiving dexmedetomidine infusions adjusted to achieve the desired level of sedation, we determined a median of five plasma dexmedetomidine concentrations each. Forty subjects were genotyped for five common CYP2A6 alleles and grouped into normal (n = 33), intermediate (n = 5), and slow metabolizers (n = 2).

RESULTS - Using a Bayesian hierarchical nonlinear mixture model, estimated dexmedetomidine clearance was 49.1 L/h (posterior mean; 95% credible interval 41.4-57.6 L/h). There were no significant differences in dexmedetomidine clearance among normal, intermediate, and slow CYP2A6 metabolizer groups.

CONCLUSION - Genetic variation in CYP2A6 does not appear to be an important determinant of dexmedetomidine clearance in ICU patients.

MeSH Terms (13)

Alleles Aryl Hydrocarbon Hydroxylases Bayes Theorem Cytochrome P-450 CYP2A6 Dexmedetomidine Female Genetic Variation Genotype Humans Hypnotics and Sedatives Intensive Care Units Male Middle Aged

Connections (1)

This publication is referenced by other Labnodes entities: